Clinical trials: Breast Cancer, Metastatic
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II
Effect of Hemp-CBD on Patients With CIPN
The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer
- Trial name
- Coala-T-CBD (NCT04398446)
- Testing
- Hemp-based CBD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Main Line Health
Neoplasms, Breast
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best) doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the tumor response rate (shrinkage or lack of growth)…
- Trial name
- NCT00371488
- Testing
- GW572016 oral tablets
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Breast Cancer With Brain Metastases
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
This study intends to conduct a small, prospective, single-center clinical study to explore and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab in HER2-positive advanced breast cancer…
- Trial name
- NCT06152822
- Testing
- pyrotinib+capecitabine+bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
HER2-positive Breast Cancer
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer
This is a multicenter, non-interventional, retrospective, real-world study that enrolled patients diagnosed with HER2-positive unresectable or metastatic breast cancer.
- Trial name
- NCT05769751
- Testing
- Electronic medical record and hospital information system or other available resources
- Where
- 5 sites in China
- Volunteers
- 865 people
- Sponsor
- Daiichi Sankyo
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00934895
- Testing
- everolimus, abraxane
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Breast Cancer
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination chemotherapy of eribulin and…
- Trial name
- ESPERO (NCT05530057)
- Testing
- Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Hospital
Advanced Metastatic Breast Cancer
Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
A Pilot study on circulating tumor DNA (ctDNA) in advanced/metastatic breast cancer with low levels of HER2 expression (HER2 low)
- Trial name
- LEGO (NCT06706557)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- European Institute of Oncology
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts…
- Trial name
- NCT06686394
- Testing
- Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Breast Cancer
Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal daunorubicin in treating patients who have…
- Trial name
- NCT00004207
- Testing
- liposomal daunorubicin citrate
- Where
- United Kingdom
- Sponsor
- University of Leicester
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074139
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Breast Cancer, Recurrent Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor
- Trial name
- CLEAR (NCT03750396)
- Testing
- Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Gastric Cancer, Colon Cancer
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Gastric Cancer, Colon Cancer, Pancreas Cancer, Esophagus Cancer
- Trial name
- NCT06010862
- Testing
- CEA CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
The purpose of this trial is to determine the safety and tolerability (maximum tolerated dose (MTD)) of weekly dinaciclib in combination with pembrolizumab in patients with advanced breast cancer.
- Trial name
- NCT01676753
- Testing
- Dinaciclib, Pembrolizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jo Chien
Breast Cancer
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and…
- Trial name
- ELENI (NCT07563595)
- Testing
- Elacestrant, Standard of care (Investigator Choice)
- Where
- 3 sites in Germany
- Volunteers
- 500 people
- Sponsor
- iOMEDICO AG